# Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC

> **NCT04147728** · PHASE2 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Stereotactic Body Radiation Therapy

## Interventions

- **DRUG:** Anlotinib
- **RADIATION:** Stereotactic Radiosurgery

## Key facts

- **NCT ID:** NCT04147728
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-24
- **Primary completion:** 2021-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147728, "Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04147728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*